Inactive Instrument

Fresenius SE & Co. KGaA Stock Other OTC

Equities

FSNUY

US35804M1053

Healthcare Facilities & Services

Sales 2024 * 23.02B 24.58B Sales 2025 * 24.04B 25.67B Capitalization 14.93B 15.94B
Net income 2024 * 1.42B 1.52B Net income 2025 * 1.77B 1.89B EV / Sales 2024 * 1.32 x
Net Debt 2024 * 15.48B 16.52B Net Debt 2025 * 14.81B 15.81B EV / Sales 2025 * 1.24 x
P/E ratio 2024 *
10.3 x
P/E ratio 2025 *
8.37 x
Employees -
Yield 2024 *
3.51%
Yield 2025 *
4%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Fresenius SE & Co. KGaA

Managers TitleAgeSince
Chief Executive Officer 55 21-04-11
Director of Finance/CFO 44 18-12-31
Compliance Officer - 23-07-17
Members of the board TitleAgeSince
Director/Board Member 69 15-05-19
Chairman 69 19-12-31
Director/Board Member 64 07-07-15
More insiders
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
Calendar
More about the company